European Child & Adolescent Psychiatry

, Volume 25, Issue 9, pp 1037–1038 | Cite as

The evidence base of methylphenidate for children and adolescents with attention-deficit hyperactivity disorder is in fact flawed

  • Ole Jakob StorebøEmail author
  • Erik Simonsen
  • Christian Gluud
Letter to the Editor

Dear Editors,

In an editorial on our Cochrane systematic review on methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) [1], Hoekstra and Buitelaar raise several points [2]. We thank them for drawing attention to our review and for agreeing with us that there are several caveats regarding the evidence trying to underpin the use of the drug for ADHD [2]. They also raise several critical comments on our review. Here we shall try to explain our standpoints on inclusion of trials; bias due to vested interests; bias risks derived by lack of blinding; and nocebo.

Re. inclusion criteria. The inclusion of the Multimodal Treatment Study of ADHD in our review is fully in accord with our protocol [1]. Here, we wrote that we would include trials with placebo or no intervention as control group [1]. Ten out of 185 trials had no intervention as comparator.

Re. bias due to vested interests. We are certainly not introducing a new ideology [3]. The AMSTAR...


Attention Deficit Hyperactivity Disorder Methylphenidate Attention Deficit Hyperactivity Disorder Attention Deficit Hyperactivity Disorder Symptom Vested Interest 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interests.


  1. 1.
    Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C (2015) Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. doi: 10.1002/14651858.CD009885.pub2 PubMedGoogle Scholar
  2. 2.
    Hoekstra Pieter J, Buitelaar Jan K (2016) Is the evidence base of methylphenidate for children and adolescents with attention–deficit/hyperactivity disorder flawed? Eur Child Adolesc Psychiatry. doi: 10.1007/s00787-016-0845-2 Google Scholar
  3. 3.
    Higgins JPT, Green S (2011) The Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. In: The Cochrane Collaboration. Available from
  4. 4.
    Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L (2012) Industry sponsorship and research outcome. Cochrane Database Syst Rev, 12:MR000033Google Scholar
  5. 5.
    Bero L (2013) Why the Cochrane risk of bias tool should include funding source as a standard item [editorial]. Cochrane Database Syst Rev, 12. doi: 10.1002/14651858.ED000075
  6. 6.
    Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J et al (2012) Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 157(6):429–438CrossRefPubMedGoogle Scholar
  7. 7.
    Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG et al (2008) Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336(7644):601–605CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Moncrieff J, Wessely S, Hardy R (2004) Active placebos versus antidepressants for depression. Cochrane Database Syst Rev, Issue 1. Art. No.: CD003012. doi: 10.1002/14651858.CD003012.pub2
  9. 9.
    Požgain I, Požgain Z, Degmečić D (2014) Placebo and nocebo effect: a mini review. Psychiatr Danub 26(2):100–107PubMedGoogle Scholar
  10. 10.
    Mitsikostas DD, Mantonakis L, Chalarakis N (2014) Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res 215(1):82–86CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Ole Jakob Storebø
    • 1
    • 2
    • 3
    Email author
  • Erik Simonsen
    • 1
    • 4
  • Christian Gluud
    • 5
    • 6
  1. 1.Psychiatric Research UnitRegion Zealand PsychiatryRegion ZealandDenmark
  2. 2.Child and Adolescent Psychiatric DepartmentRegion ZealandDenmark
  3. 3.Department of Psychology, Faculty of Health ScienceUniversity of Southern DenmarkOdenseDenmark
  4. 4.Institute of Clinical Medicine and Faculty of Health and Medical SciencesCopenhagen UniversityCopenhagenDenmark
  5. 5.The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, RigshospitaletCopenhagen University HospitalCopenhagenDenmark
  6. 6.The Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, RigshospitaletCopenhagen University HospitalCopenhagenDenmark

Personalised recommendations